







Impact for Patients and Healthcare Providers

- Validated digital outcomes to predict clinical outcomes
- Improved personalised medicine
- Benefits for the healthcare of citizens in the EU and globally
- Key regulatory and health stakeholder approval for digital mobility assessment
- More precise classification of patients according to their disabilities, helping the process of patient stratification
- General applicability that allows wide adoption of the mobility assessment platform beyond the disease groups included in Mobilise-D
- Enduring impact by establishing the largest biobank of digital mobility data to support ongoing algorithm development and validation

Mobilise-D: Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement

The Mobilise-D consortium consists of 34 partner institutions from Europe and the USA. Over 150 professionals with technical, clinical, and regulatory expertise work together to bring digital mobility outcomes to the clinic.

Contact: info@mobilise-d.eu

 www.mobilise-d.eu
 [@mobilised](https://www.facebook.com/mobilised)
 [@mobilise_d](https://twitter.com/mobilise_d)
 [mobilise-d](https://www.linkedin.com/company/mobilise-d)



Mobilise-D has received funding from IMI 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).



«Mobility loss is a vital sign, just like blood pressure or temperature, that can be used to monitor and predict health status as well as disease progression»



Our Goals



Digital mobility assessment



Regulatory acceptance for clinical use



Improved patient care



Mobilise-D provides a unique measurement tool:

- For real-world digital mobility assessment.
- That will be technically and clinically validated in different patient groups.

Mobilise-D will focus on conditions that affect mobility, namely chronic obstructive pulmonary disease, Parkinson's disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

Mobilise-D boosts and fosters:

- Engagement of patient organisations and other stakeholders in all developments.
- Clear definitions of mobility parameters that can be used as new primary clinical endpoints in drug development trials.
- A pathway to facilitate the process of regulatory approval.

- Mobility is an important marker of health. Loss of mobility – especially difficulty walking - is a key determinant of whether people can remain independent as they get older or sick.
- Changes in walking speed over time, more frequent loss of balance, or increased stiffness during walking, are correlated with increased risk for disease and disability.
- Your gait, posture, and pace may also be broadcasting clues about your health.

Challenge in digital mobility assessment:

Accurately assessing people's mobility, especially in the daily real life world, is extremely complex and currently, there are no validated good solutions.

There is an urgent need to exploit modern technologies in digital mobility assessment to accelerate development of interventions and treatment, thereby improving healthcare pathways and the lives of patients.

